Habitual use of glucosamine and adverse liver outcomes among patients with type 2 diabetes and MASLD.

Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE

Publication: Malden, MA : Wiley-Blackwell
Original Publication: Oxford, UK : Blackwell Munksgaard, c2003-

Diabetes Mellitus, Type 2*/complications ; Glucosamine*/therapeutic use ; Glucosamine*/adverse effects ; Dietary Supplements*/adverse effects; Humans ; Female ; Male ; Middle Aged ; Prospective Studies ; Aged ; United Kingdom/epidemiology ; Risk Factors ; Fatty Liver

Background: Glucosamine is a dietary supplement commonly used to support joint health. However, there has been interest in exploring other effects of glucosamine on health outcomes due to its ant-inflammation effect.
Objective: This study compared the risks of major adverse liver outcomes (MALOs) between regular users and non-users of glucosamine among patients with type 2 diabetes and metabolic dysfunction associated steatotic liver disease (MASLD) using the data from a large prospective cohort study.
Methods: Demographic, anthropometric, laboratory and medication prescription information among 18 753 patients with type 2 diabetes and MASLD was obtained from the UK Biobank. MASLD was identified based on hepatic steatosis defined by fatty liver index ≥60 plus the presence of any clues of metabolic dysregulation and cardio-metabolic risk factors, excluding patients with moderate to severe alcohol consumption.
Results: During a mean follow-up of 11.4 years, 826 incident MALOs events were recorded. Patients not regularly using glucosamine compared with patients using glucosamine showed a significantly higher risk of the composite MALOs (HR 1.36, 95% confidence interval [CI] 1.09-1.69) as well as most individual MALOs except for ascites. The multivariable-adjusted HRs of MALOs within 3, 5 and 10 years among non-users of glucosamine compared with regular users were 1.79 (95% CI .69-2.03), 1.88 (95% CI 1.21-2.54) and 1.32 (95% CI 1.05-1.72), respectively. Further subgroup analyses in participants with different baseline characteristics and sensitivity analyses excluding participants who regularly took any other supplements and participants who used self-reports to diagnose diabetes confirmed the findings.
Conclusions: The present study indicated that habitual use of glucosamine was associated with a low risk of individual and composite MALOs among patients with type 2 diabetes and MASLD.
(© 2024 The Author(s). Liver International published by John Wiley & Sons Ltd.)

Jia W , Weng J , Zhu D , et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. 2019;35(6):e3158.
Loomba R , Friedman SL , Shulman GI . Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537‐2564.
Negro F . Natural history of NASH and HCC. Liver Int. 2020;40(Suppl 1):72‐76.
Tomic D , Shaw JE , Magliano DJ . The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(9):525‐539.
Ma H , Li X , Zhou T , et al. Glucosamine use, inflammation, and genetic susceptibility, and incidence of type 2 diabetes: a prospective study in UK Biobank. Diabetes Care. 2020;43(4):719‐725.
Ma H , Li X , Sun D , et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019;365:l1628.
Li FX , Zhao HY , Lin TF , et al. Regular glucosamine use may have different roles in the risk of site‐specific cancers: findings from a large prospective cohort. Cancer Epidemiol Biomarkers Prev. 2023;32(4):531‐541.
Zhang XR , Zhang PD , Li ZH , et al. Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: a large prospective cohort study. Br J Nutr. 2022;128(4):721‐732.
Xu C , Hou Y , Fang X , Yang H , Cao Z . The role of type 2 diabetes in the association between habitual glucosamine use and dementia: a prospective cohort study. Alzheimers Res Ther. 2022;14(1):184.
Bell GA , Kantor ED , Lampe JW , Shen DD , White E . Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012;27(8):593‐603.
Zhou J , Wu Z , Lin Z , Wang W , Wan R , Liu T . Association between glucosamine use and cancer mortality: a large prospective cohort study. Front Nutr. 2022;9:947818.
Bedogni G , Bellentani S , Miglioli L , et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
Eslam M , Newsome PN , Sarin SK , et al. A new definition for metabolic dysfunction‐associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202‐209.
Daviet R , Aydogan G , Jagannathan K , et al. Associations between alcohol consumption and gray and white matter volumes in the UK Biobank. Nat Commun. 2022;13(1):1175.
Topiwala A , Wang C , Ebmeier KP , et al. Associations between moderate alcohol consumption, brain iron, and cognition in UK Biobank participants: observational and Mendelian randomization analyses. PLoS Med. 2022;19(7):e1004039.
Han H , Cao Y , Feng C , et al. Association of a healthy lifestyle with all‐cause and cause‐specific mortality among individuals with Type 2 diabetes: a prospective study in UK Biobank. Diabetes Care. 2022;45(2):319‐329.
Mozaffarian D . Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016;133(2):187‐225.
Said MA , Verweij N , van der Harst P . Associations of combined genetic and lifestyle risks with incident cardiovascular disease and diabetes in the UK Biobank study. JAMA Cardiol. 2018;3(8):693‐702.
Sterling RK , Lissen E , Clumeck N , et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317‐1325.
Sibbritt D , Adams J , Lui CW , Broom A , Wardle J . Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One. 2012;7(7):e41540.
Jordan KM , Arden NK , Doherty M , et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145‐1155.
Cannito S , Dianzani U , Parola M , Albano E , Sutti S . Inflammatory processes involved in NASH‐related hepatocellular carcinoma. Biosci Rep. 2023;43(1):BSR20221271.
Kang GG , Trevaskis NL , Murphy AJ , Febbraio MA . Diet‐induced gut dysbiosis and inflammation: key drivers of obesity‐driven NASH. iScience. 2023;26(1):105905.
Laursen TL , Mellemkjær A , Møller HJ , Grønbæk H , Kazankov K . Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2022;26(8):697‐705.
Wiering L , Tacke F . Treating inflammation to combat non‐alcoholic fatty liver disease. J Endocrinol. 2023;256(1):e220194.
Raptis DD , Mantzoros CS , Polyzos SA . Fibroblast growth factor‐21 as a potential therapeutic target of nonalcoholic fatty liver disease. Ther Clin Risk Manag. 2023;19:77‐96.
Katsarou A , Moustakas II , Pyrina I , Lembessis P , Koutsilieris M , Chatzigeorgiou A . Metabolic inflammation as an instigator of fibrosis during non‐alcoholic fatty liver disease. World J Gastroenterol. 2020;26(17):1993‐2011.
Sakai M . Exploring the signal‐dependent transcriptional regulation involved in the liver pathology of type 2 diabetes. Diabetol Int. 2023;14(1):15‐20.
Werlen G , Li ML , Tottone L , et al. Dietary glucosamine overcomes the defects in αβ‐T cell ontogeny caused by the loss of de novo hexosamine biosynthesis. Nat Commun. 2022;13(1):7404.
Reese TA , Liang HE , Tager AM , et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature. 2007;447(7140):92‐96.
Li F , Zhang Z , Bai Y , et al. Glucosamine improves non‐alcoholic fatty liver disease induced by high‐fat and high‐sugar diet through regulating intestinal barrier function, liver inflammation, and lipid metabolism. Molecules. 2023;28(19):6918.
Andrade C . The ceiling effect, the floor effect, and the importance of active and placebo control arms in randomized controlled trials of an investigational drug. Indian J Psychol Med. 2021;43(4):360‐361.

Program of Shanghai Academic Research Leader

Keywords: MALO; MASLD; glucosamine

N08U5BOQ1K (Glucosamine)

Date Created: 20240606 Date Completed: 20240829 Latest Revision: 20240829

20240830

10.1111/liv.16001

38842441